Kidney Fibrosis Treatment Market Report 2025-2034: Industry Overview, Drivers, And Forecast Analysis

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current Kidney Fibrosis Treatment Market Size and Its Estimated Growth Rate?
In recent times, there has been substantial growth in the kidney fibrosis treatment market size. The market value is projected to increase from $6.93 billion in 2024 to $7.58 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth during the historic period include increased investment in research and development for fibrosis-specific treatment methods, escalated government funding for kidney disease control initiatives, enhancement in patient awareness regarding kidney transplantation and fibrosis treatment alternatives, augmentation in healare infrastructure, and a surge in the elderly population.

The market for kidney fibrosis treatment is projected to experience significant expansion in the coming years. It is predicted to reach $10.78 billion by 2029, with a compound annual growth rate (CAGR) of 11.7%. This surge during the forecasted period is due to factors like the rising incidence of chronic kidney diseases, increased need for advanced renal fibrosis therapies, heightened awareness for early kidney fibrosis detection, the growing use of personalized medicine in treating kidney diseases, and an escalating prevalence of diabetes and hypertension. Technology advancements in early detection and diagnostic techniques, progress in gene therapy, integration of technology in telemedicine and remote surveillance, advancements in stem cell therapies, and improved drug delivery systems are major trends expected to influence the market growth during the forecast period.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

How Are Emerging Segments Shaping the Kidney Fibrosis Treatment Market Landscape?
The kidney fibrosis treatment market covered in this report is segmented -

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types
2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests, Kidney Biopsy
3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications
4) By End-User: Clinics, Research Center, Hospitals

Subsegments:
1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril
2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan
3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone
4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors
5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat
6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Which Growth Factors Are Influencing Kidney Fibrosis Treatment Market Expansion?
The rising occurrence of chronic kidney illnesses is anticipated to steer the growth of the kidney fibrosis treatment market in the future. Chronic kidney disease (CKD), which involves a slow loss of kidney function over time due to conditions like diabetes or hypertension, leads to the buildup of waste products in the body. The escalating prevalence of chronic kidney disease (CKD) is mostly prompted by the growing incidence of diabetes, which harms kidney blood vessels and impacts their filtering capacity. Kidney fibrosis treatment aids chronic kidney disease (CKD) patients by focusing on the scarring of kidney tissue, subduing inflammation, and decelerating the advancement of kidney damage, thereby preserving kidney function. For instance, in May 2024, the Centers for Disease Control and Prevention (CDC), a US public health agency, estimated that about 14% of U.S. adults, which is roughly 35.5 million people, might have chronic kidney illnesses. Hence, the escalating prevalence of chronic kidney diseases is propelling the growth of the kidney fibrosis treatment market. Growth in the kidney fibrosis treatment market is being spurred by an increase in clinical trial activity, driven by the demand for innovative and personalized therapies. Clinical trials, which are research studies performed on humans to determine the safety, effectiveness, and side effects of medical treatments or interventions, are proliferating due to the rising demand for innovative, personalized treatments that necessitate thorough safety and efficacy tests. Clinical trials contribute to kidney fibrosis treatment by providing a specific area to trial novel anti-fibrotic therapies, allowing researchers to assess the effectiveness of new drugs in slowing or reversing kidney damage. For instance, according to a report by the Association of the British Pharmaceutical Industry, a trade association based in the UK, in November 2023, there was a 15% annual rise in recruitment for industry clinical trials in the UK, climbing from 36,722 participants in 2021-22 to 42,088 in 2022-23. Therefore, the growth of the kidney fibrosis treatment market is fuelled by increasing clinical trials.

Who Are the Dominant Players Across Different Kidney Fibrosis Treatment Market Segments?
Major companies operating in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Geographic Regions Are Expected to Dominate the Kidney Fibrosis Treatment Market in the Coming Years?
North America was the largest region in the kidney fibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Kidney Fibrosis Treatment Market?
2. What is the CAGR expected in the Kidney Fibrosis Treatment Market?
3. What Are the Key Innovations Transforming the Kidney Fibrosis Treatment Industry?
4. Which Region Is Leading the Kidney Fibrosis Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.